Fachri Salim personal page - To The Moon

Fachri Salim

Fachri Salim

BELAJARLAH SEBELUM BELAJAR DILARANG

0Follow

0Followers

0Topic

0Badge

2023-11-15

Wow

5 Stocks You Can Confidently Invest $500 In Right Now

2023-11-15

Good

3 Growth Stocks to Buy That Could Be Massive Long-Term Winners

2023-11-15

"Jika keberhasilan adalah kunci kesuksesan, maka mungkin di dunia ini banyak orang yang tidak sukses karna egonya"

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4163116133746432","uuid":"4163116133746432","gmtCreate":1700013011762,"gmtModify":1700025505956,"name":"Fachri Salim","pinyin":"fachrisalimfachrisalim","introduction":"","introductionEn":"","signature":"BELAJARLAH SEBELUM BELAJAR DILARANG","avatar":"https://community-static.tradeup.com/news/878ebcbca71067e86825377dd1791b5e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":241646362833088,"gmtCreate":1700024197848,"gmtModify":1700027131107,"author":{"id":"4163116133746432","authorId":"4163116133746432","name":"Fachri Salim","avatar":"https://community-static.tradeup.com/news/878ebcbca71067e86825377dd1791b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4163116133746432","authorIdStr":"4163116133746432"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/241646362833088","repostId":"2383047746","repostType":2,"repost":{"id":"2383047746","pubTimestamp":1700020269,"share":"https://ttm.financial/m/news/2383047746?lang=&edition=fundamental","pubTime":"2023-11-15 11:51","market":"us","language":"en","title":"5 Stocks You Can Confidently Invest $500 In Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2383047746","media":"Motley Fool","summary":"Simplicity, sustainability, and sheer market dominance are the keys to a truly trustworthy long-term ticker.","content":"<html><head></head><body><p>Do you prefer a more passive, long-term approach to investing that doesn&#39;t require constant monitoring and updating of your portfolio? That&#39;s fine. In fact, it&#39;s great. Investors employing a simpler &#34;less is more&#34; approach often end up outperforming their peers.</p><p>The key to success with such a strategy is just finding the right stocks to begin with. If you are just starting out as an investor but only have so much available to invest -- say $500 -- you want to start out with solid choices you know will do well so you can grow that initial investment. You also need to know these choices will be fine in the long run, and able to shrug off any short-term challenges.</p><p>With that as the backdrop, here&#39;s a rundown of five different stocks you can confidently invest $500 in right now and not worry about them too much for the next several years.</p><h2 id=\"id_3620851651\">1. <a href=\"https://laohu8.com/S/PG\">Procter &amp; Gamble</a></h2><p>You&#39;ve heard of the company. And you&#39;re likely to also be a customer without even realizing it. Procter &amp; Gamble is parent to several popular brands of consumer goods, including Tide laundry detergent, Gillette razors, Luvs and Pampers diapers, Cascade dishwasher detergent, Bounty paper towels, and more.</p><p>Its products aren&#39;t just familiar, either. In market research outfit BrandSpark&#39;s most recent look at the market, Procter &amp; Gamble boasted a leading 23 of the country&#39;s most trusted brand names; Tide alone won in five different laundry categories.</p><p>This is no small matter. See, although brand recognition alone doesn&#39;t inherently guarantee profitability, market dominance goes a long way in ensuring a leading brand remains a leading brand. Not only does Procter &amp; Gamble enjoy all the advantages of scale, like relatively lower production and operating costs as well as sales leverage with retailers, but it also simply has more products to cross-sell. P&amp;G can also afford to be one of the world&#39;s biggest advertisers.</p><p>Connect the dots. It&#39;s unlikely Procter &amp; Gamble is going to be dethroned anytime soon, if ever.</p><h2 id=\"id_3269544970\">2. <a href=\"https://laohu8.com/S/AAPL\">Apple</a></h2><p>Here&#39;s another company that doesn&#39;t need much of an introduction. Apple, of course, makes the world&#39;s single most popular smartphone -- the iPhone. Yes, Samsung technically sells more total smartphones, but in a variety of models and price ranges. Apple also generates far more smartphone revenue than any of its rivals due to the iPhone&#39;s premium pricing.</p><p>Loyalty to the iOS operating system powering iPhones is sky-high, too, with market research firm Consumer Intelligence Research Partners reporting that 94% of iOS users (most of them being iPhone users) plan on sticking with the operating system when it&#39;s time to upgrade their devices. Consumer Intelligence Research Partners adds that between early last year and early this year, 15% of iPhone purchases made within the United States were made by former users of Samsung&#39;s Android smartphones. Both measures are far stronger than Android&#39;s appeal and loyalty.</p><p>Although the iPhone is a powerhouse product accounting for more than half of the company&#39;s revenue, it&#39;s not the only reason to step into Apple for the long haul. The popular device is increasingly a means to an end, generating additional revenue by facilitating the sale of apps, music, and video entertainment. These digital services now account for around one-fourth of Apple&#39;s top line and even more of its bottom line.</p><p>Apps and subscriptions only fuel consumer loyalty to Apple&#39;s iOS digital ecosystem, of course. People are not only already familiar with the operating system, but they&#39;ve already paid for many of the apps installed on previous versions of their smartphones.</p><h2 id=\"id_3507458951\">3. <a href=\"https://laohu8.com/S/V\">Visa</a></h2><p>This is yet another company you&#39;re more than familiar with. Visa is the world&#39;s biggest credit card middleman (outside of China, anyway), handling the purchase of $14.8 trillion worth of goods and services in its recently ended fiscal year. That&#39;s more than 259 billion total transactions from a crowd wielding more than 4 billion Visa credit and debit cards.</p><p>Visa&#39;s sheer reach is only half the reason to own the stock, however. The other half is the way consumer spending is evolving. Cash is slowly but surely going away, displaced by cards. The U.S. Federal Reserve reports that back in 2012, cash was used to handle 40% of purchases made within the United States. Now, that number has been dialed back to only 18%. During this time, debit and credit card usage has grown from 44% of transactions to 60%.</p><p>Yet, there&#39;s room remaining for both of these trends to continue.</p><p>This shift, of course, reflects the growing convenience of cards and the growing inconvenience of paper and coins. It&#39;s now common within the United States to purchase things like groceries or even pay your wireless phone bill with a credit card, and more so every day.</p><p>Visa may never be a high-growth stock. As long as sellers and buyers want to connect with one another, though, Visa&#39;s service will be a necessary one.</p><h2 id=\"id_1739133160\">4. <a href=\"https://laohu8.com/S/ADBE\">Adobe</a></h2><p>You probably know the name as the developer of image-editing software Photoshop or the premier name in digital PDF (portable document file) solutions. And it still offers both.</p><p>However, Adobe is so much more than Photoshop and PDFs. The company offers a full-blown suite of digital tools aimed at the business market. Stock photography, generative AI, 3D modeling, animation, web traffic analytics, e-commerce tools, targeted marketing, and digital data collection (and more) are all in its wheelhouse now.</p><p>That&#39;s not the evolution that makes Adobe such a worry-free investment, though. You can confidently pour at least a portion of your idle cash into it at this time because of the way it now offers its software to customers. While you can still purchase it outright on a one-time basis, most users now opt for the subscription-based, cloud-accessed versions of its tools. Not only are these tools always up to date and accessible from anywhere, but this model is also often more cost-effective for the end-user. It&#39;s good for Adobe and its investors, too, as recurring revenue is also predictable revenue.</p><p>To this end, Adobe&#39;s annualized recurring revenue run rate now stands at $14.6 billion, while $15.7 billion worth of this business is already lined up and waiting to be booked. For perspective, Adobe has done about $18.9 billion worth of business over the course of the past four quarters.</p><h2 id=\"id_3283725545\">5. <a href=\"https://laohu8.com/S/KO\">Coca-Cola</a></h2><p>Last but not least, add Coca-Cola to your list of stocks you can confidently step into right now.</p><p>Like Adobe, Procter &amp; Gamble, Apple, and Visa, the big draw here is once again the habitual, recurring purchase of its products -- all of them. Yes, there&#39;s its market-leading namesake cola. The company isn&#39;t just carbonated beverages, though. This is also the name behind Dasani water, Gold Peak tea, Minute Maid juice, and others. It&#39;s always got a beverage product to sell someone.</p><p>The key selling feature of Coca-Cola stock, however, is its dividend. The current dividend yield is a healthy 3.2%, but more than that, it&#39;s a dividend that&#39;s been raised every single year for the past 61 years.</p><p>Don&#39;t look for this streak to be snapped anytime soon, either. See, the beverage giant has spent the past several years selling its bottling operations back to local bottlers so it can better focus on what it does best. That&#39;s marketing and licensing its flavors and brand names. And it&#39;s very,<em> very</em> good at it; there&#39;s a reason brand names and their corresponding brand logos are among the most recognized in the world.</p><p>While this strategic shift means less net revenue, since profit margins on royalties are much higher than margins on bottling, The Coca-Cola Company is actually set to make more net income now than it was earning then.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d3862e9a8f827075ba0534701a963021\" alt=\"KO Revenue (Quarterly) data by YCharts.\" title=\"KO Revenue (Quarterly) data by YCharts.\" tg-width=\"720\" tg-height=\"500\"/><span>KO Revenue (Quarterly) data by YCharts.</span></p><p>As the chart above also illustrates, Coca-Cola is making far more than enough money to continue funding its dividend. It&#39;s well-shielded should temporary turbulence strike.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks You Can Confidently Invest $500 In Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks You Can Confidently Invest $500 In Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-15 11:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/11/14/5-stocks-you-can-confidently-invest-500-in-right-n/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you prefer a more passive, long-term approach to investing that doesn't require constant monitoring and updating of your portfolio? That's fine. In fact, it's great. Investors employing a simpler \"...</p>\n\n<a href=\"https://www.fool.com/investing/2023/11/14/5-stocks-you-can-confidently-invest-500-in-right-n/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"V":"Visa","PG":"宝洁","ADBE":"Adobe","KO":"可口可乐","AAPL":"苹果"},"source_url":"https://www.fool.com/investing/2023/11/14/5-stocks-you-can-confidently-invest-500-in-right-n/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2383047746","content_text":"Do you prefer a more passive, long-term approach to investing that doesn't require constant monitoring and updating of your portfolio? That's fine. In fact, it's great. Investors employing a simpler \"less is more\" approach often end up outperforming their peers.The key to success with such a strategy is just finding the right stocks to begin with. If you are just starting out as an investor but only have so much available to invest -- say $500 -- you want to start out with solid choices you know will do well so you can grow that initial investment. You also need to know these choices will be fine in the long run, and able to shrug off any short-term challenges.With that as the backdrop, here's a rundown of five different stocks you can confidently invest $500 in right now and not worry about them too much for the next several years.1. Procter & GambleYou've heard of the company. And you're likely to also be a customer without even realizing it. Procter & Gamble is parent to several popular brands of consumer goods, including Tide laundry detergent, Gillette razors, Luvs and Pampers diapers, Cascade dishwasher detergent, Bounty paper towels, and more.Its products aren't just familiar, either. In market research outfit BrandSpark's most recent look at the market, Procter & Gamble boasted a leading 23 of the country's most trusted brand names; Tide alone won in five different laundry categories.This is no small matter. See, although brand recognition alone doesn't inherently guarantee profitability, market dominance goes a long way in ensuring a leading brand remains a leading brand. Not only does Procter & Gamble enjoy all the advantages of scale, like relatively lower production and operating costs as well as sales leverage with retailers, but it also simply has more products to cross-sell. P&G can also afford to be one of the world's biggest advertisers.Connect the dots. It's unlikely Procter & Gamble is going to be dethroned anytime soon, if ever.2. AppleHere's another company that doesn't need much of an introduction. Apple, of course, makes the world's single most popular smartphone -- the iPhone. Yes, Samsung technically sells more total smartphones, but in a variety of models and price ranges. Apple also generates far more smartphone revenue than any of its rivals due to the iPhone's premium pricing.Loyalty to the iOS operating system powering iPhones is sky-high, too, with market research firm Consumer Intelligence Research Partners reporting that 94% of iOS users (most of them being iPhone users) plan on sticking with the operating system when it's time to upgrade their devices. Consumer Intelligence Research Partners adds that between early last year and early this year, 15% of iPhone purchases made within the United States were made by former users of Samsung's Android smartphones. Both measures are far stronger than Android's appeal and loyalty.Although the iPhone is a powerhouse product accounting for more than half of the company's revenue, it's not the only reason to step into Apple for the long haul. The popular device is increasingly a means to an end, generating additional revenue by facilitating the sale of apps, music, and video entertainment. These digital services now account for around one-fourth of Apple's top line and even more of its bottom line.Apps and subscriptions only fuel consumer loyalty to Apple's iOS digital ecosystem, of course. People are not only already familiar with the operating system, but they've already paid for many of the apps installed on previous versions of their smartphones.3. VisaThis is yet another company you're more than familiar with. Visa is the world's biggest credit card middleman (outside of China, anyway), handling the purchase of $14.8 trillion worth of goods and services in its recently ended fiscal year. That's more than 259 billion total transactions from a crowd wielding more than 4 billion Visa credit and debit cards.Visa's sheer reach is only half the reason to own the stock, however. The other half is the way consumer spending is evolving. Cash is slowly but surely going away, displaced by cards. The U.S. Federal Reserve reports that back in 2012, cash was used to handle 40% of purchases made within the United States. Now, that number has been dialed back to only 18%. During this time, debit and credit card usage has grown from 44% of transactions to 60%.Yet, there's room remaining for both of these trends to continue.This shift, of course, reflects the growing convenience of cards and the growing inconvenience of paper and coins. It's now common within the United States to purchase things like groceries or even pay your wireless phone bill with a credit card, and more so every day.Visa may never be a high-growth stock. As long as sellers and buyers want to connect with one another, though, Visa's service will be a necessary one.4. AdobeYou probably know the name as the developer of image-editing software Photoshop or the premier name in digital PDF (portable document file) solutions. And it still offers both.However, Adobe is so much more than Photoshop and PDFs. The company offers a full-blown suite of digital tools aimed at the business market. Stock photography, generative AI, 3D modeling, animation, web traffic analytics, e-commerce tools, targeted marketing, and digital data collection (and more) are all in its wheelhouse now.That's not the evolution that makes Adobe such a worry-free investment, though. You can confidently pour at least a portion of your idle cash into it at this time because of the way it now offers its software to customers. While you can still purchase it outright on a one-time basis, most users now opt for the subscription-based, cloud-accessed versions of its tools. Not only are these tools always up to date and accessible from anywhere, but this model is also often more cost-effective for the end-user. It's good for Adobe and its investors, too, as recurring revenue is also predictable revenue.To this end, Adobe's annualized recurring revenue run rate now stands at $14.6 billion, while $15.7 billion worth of this business is already lined up and waiting to be booked. For perspective, Adobe has done about $18.9 billion worth of business over the course of the past four quarters.5. Coca-ColaLast but not least, add Coca-Cola to your list of stocks you can confidently step into right now.Like Adobe, Procter & Gamble, Apple, and Visa, the big draw here is once again the habitual, recurring purchase of its products -- all of them. Yes, there's its market-leading namesake cola. The company isn't just carbonated beverages, though. This is also the name behind Dasani water, Gold Peak tea, Minute Maid juice, and others. It's always got a beverage product to sell someone.The key selling feature of Coca-Cola stock, however, is its dividend. The current dividend yield is a healthy 3.2%, but more than that, it's a dividend that's been raised every single year for the past 61 years.Don't look for this streak to be snapped anytime soon, either. See, the beverage giant has spent the past several years selling its bottling operations back to local bottlers so it can better focus on what it does best. That's marketing and licensing its flavors and brand names. And it's very, very good at it; there's a reason brand names and their corresponding brand logos are among the most recognized in the world.While this strategic shift means less net revenue, since profit margins on royalties are much higher than margins on bottling, The Coca-Cola Company is actually set to make more net income now than it was earning then.KO Revenue (Quarterly) data by YCharts.As the chart above also illustrates, Coca-Cola is making far more than enough money to continue funding its dividend. It's well-shielded should temporary turbulence strike.","news_type":1},"isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":241636781736168,"gmtCreate":1700021760032,"gmtModify":1700026846468,"author":{"id":"4163116133746432","authorId":"4163116133746432","name":"Fachri Salim","avatar":"https://community-static.tradeup.com/news/878ebcbca71067e86825377dd1791b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4163116133746432","authorIdStr":"4163116133746432"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/241636781736168","repostId":"2383028540","repostType":2,"repost":{"id":"2383028540","pubTimestamp":1699927200,"share":"https://ttm.financial/m/news/2383028540?lang=&edition=fundamental","pubTime":"2023-11-14 10:00","market":"fut","language":"en","title":"3 Growth Stocks to Buy That Could Be Massive Long-Term Winners","url":"https://stock-news.laohu8.com/highlight/detail?id=2383028540","media":"Motley Fool","summary":"A red-hot product or service right now doesn't mean much if demand for it isn't going to last.","content":"<html><body><div><p>It's not terribly difficult to identify the sizzling growth stocks of the moment, drawing heaps of enthusiasm on Wall Street. It can be a bit of a challenge, however, to spot those companies that have long-term staying power and are going to still be thriving many years into the future. It requires a product or service in perpetual demand as well as the capacity to adapt as the marketplace evolves.</p><p>With that as the backdrop, here's a rundown of three growth stocks that could be massive long-term winners.</p><h2>1. Nvidia</h2><p>You probably know the name <strong>Nvidia</strong> <span>(NVDA<span> 2.12%</span>)</span> as a manufacturer of computer hardware -- specifically, a maker of high-performance graphics processors that hardcore video gamers need. The company still makes great graphic cards. As it turns out, though, the same technology is perfectly suited to handle all the calculations needed in artificial intelligence (AI) applications.</p><p>That's how Nvidia's data center business (which largely serves the AI market) became its single-biggest profit center, accounting for over half of the company's revenue. Superior technology is also how Nvidia became the leader of the world's AI hardware market; some estimates put its market share reach in the ballpark of 90%.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"204770\" :show_benchmark_compare=\"false\" amount_change=\"10.33\" average_volume=\"49,723,415\" company_name=\"Nvidia\" current_price=\"496.53\" daily_high=\"497.63\" daily_low=\"492.71\" default_period=\"OneYear\" dividend_yield=\"0.03%\" exchange=\"NASDAQ\" fifty_two_week_high=\"502.66\" fifty_two_week_low=\"138.84\" gross_margin=\"64.62\" logo=\"https://g.foolcdn.com/art/companylogos/mark/NVDA.png\" market_cap=\"$1,201B\" pe_ratio=\"117.45\" percent_change=\"2.12\" symbol=\"NVDA\" volume=\"6,883,789\"></app></div><p>And that's what makes this stock such a great long-term prospect -- the AI movement has still only scratched the surface of its potential. Market research outfit Technavio forecasts annualized AI chip market growth of more than 60% through 2027. Nvidia is prepared to capture more than its fair share of this growth by virtue of its software's ability to provide off-the-shelf, turnkey AI solutions. Precedence Research believes the software sliver of the AI market is on pace to grow by an average pace of 23% through 2032.</p><div><div></div></div><p>Nvidia shares are seemingly priced at somewhat frothy levels right now -- up more than 300% just since last October's low. Just don't be too stingy or short-sighted if you want in. The analyst community's current consensus target stands at $647.20, which is still 38% above the stock's present price. Nvidia shares' current price is also only a relatively modest 28 times next year's expected per-share earnings. This recent rally is pretty well justified.</p><h2>2. Icon PLC</h2><p>While Nvidia may be a household name, <strong>Icon PLC</strong> <span>(ICLR<span> 3.51%</span>)</span> isn't. There's a very good chance you or someone in your household has benefited from Icon's service, however, without realizing it.</p><p>In simplest terms, Icon PLC helps more familiar pharmaceutical names develop their drugs. It's a clinical research organization, or CRO, meaning that it handles clinical testing for drug companies that don't want to deal with the distraction or cost of handling such duties on their own. The Ireland-based company solidifies its relationships with add-on services like consulting, any labwork required for a particular trial, and patient recruitment and retention.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"203988\" :show_benchmark_compare=\"false\" amount_change=\"9.01\" average_volume=\"529,308\" company_name=\"Icon Public\" current_price=\"265.92\" daily_high=\"265.92\" daily_low=\"260.79\" default_period=\"OneYear\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"268.07\" fifty_two_week_low=\"181.92\" gross_margin=\"22.24\" logo=\"https://g.foolcdn.com/art/companylogos/mark/ICLR.png\" market_cap=\"$21B\" pe_ratio=\"41.01\" percent_change=\"3.51\" symbol=\"ICLR\" volume=\"23,270\"></app></div><p>It's a true win-win, too. That's because the logistics of clinical drug trials are complicated and expensive, particularly for smaller developers that may only be working on a few projects -- or maybe even just one drug. They're also risky. A University of Michigan study in the journal <em>Science Direct</em> points out that 90% of drugs fail to win approval. Of those, roughly half fail because of clinical inefficiency.</p><div><div></div></div><p>It's often cheaper, easier, faster, and ultimately safer to punt this work to experts in this sliver of the pharmaceutical market. And Icon's a go-to name in the business. It's already done it all and is good at what it does. More than a decade's worth of mostly uninterrupted revenue growth says so, as do its income and earnings before interest, taxes, depreciation, and amortization (EBITDA) growth histories.</p><p><img src=\"https://media.ycharts.com/charts/ad6cb845d86b29a78d3a6b2bd421c18c.png\"/></p><p>ICLR Revenue (Quarterly) data by YCharts.</p><p>Investors have good reason to expect more of this reliable growth going forward, too. That's because there's never apt to be a time when the world will stop looking for newer and better drugs. The increasing cost and complexity of drug development also work to Icon's advantage.</p><h2>3. Novo Nordisk</h2><p>Last but not least (and speaking of pharmaceuticals), shares of <strong>Novo Nordisk</strong> <span>(NVO<span> -1.41%</span>)</span> offer lots of long-term growth potential. If it seems like you've heard this name being discussed more than usual of late, you're not imagining things. Credit its drugs Ozempic and Wegovy, mostly.</p><div><div></div></div><p>Although it was approved back in the middle of 2021, production delays didn't allow weight-loss drug Wegovy to reach the market until late last year. Sales are, unsurprisingly, picking up steam, stoking interest in the stock. Ozempic is a diabetes treatment that's been on the market since 2016, but it's increasingly being prescribed off-label as an obesity drug as well.</p><p><strong>Eli Lilly</strong>'s diabetes treatment Mounjaro was also just approved for weight loss, thrusting all of these options into the comparative spotlight and pushing investors into a bit of a frenzy as a result.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"204773\" :show_benchmark_compare=\"false\" amount_change=\"-1.43\" average_volume=\"4,531,643\" company_name=\"Novo Nordisk\" current_price=\"99.36\" daily_high=\"99.79\" daily_low=\"99.17\" default_period=\"OneYear\" dividend_yield=\"1.24%\" exchange=\"NYSE\" fifty_two_week_high=\"104.00\" fifty_two_week_low=\"55.95\" gross_margin=\"84.16\" logo=\"https://g.foolcdn.com/art/companylogos/mark/NVO.png\" market_cap=\"$2,755B\" pe_ratio=\"23.87\" percent_change=\"-1.41\" symbol=\"NVO\" volume=\"748,555\"></app></div><p>The thing is, there's arguably enough room in the market for Novo Nordisk and any current or prospective competitors. <strong>Goldman Sachs</strong> estimates the anti-obesity drug market will swell from around $6 billion this year to a whopping $100 billion as soon as 2030, once more overweight consumers learn about them and their efficacy.</p><p>Then there's the other reason to step into a Novo Nordisk position for the long haul -- the rest of its portfolio and pipeline. The company is a major player in the diabetes/insulin arena, with its products accounting for around half of the global GLP-1 insulin markets. Much of this business will likely remain intact, too, even if the world starts losing weight thanks to the mainstreaming of weight-loss pills and injections.</p><p>A research study recently published in <em>The Lancet</em> indicates the number of people living with type 2 diabetes could sell from 529 million now to a worldwide total of more than 1.3 billion by 2050. Novo Nordisk should be able to leverage its existing reach to win more than its fair share of whatever growth awaits.</p><div></div></div></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Buy That Could Be Massive Long-Term Winners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Buy That Could Be Massive Long-Term Winners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-14 10:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/11/14/3-growth-stocks-to-buy-that-could-be-massive-long/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's not terribly difficult to identify the sizzling growth stocks of the moment, drawing heaps of enthusiasm on Wall Street. It can be a bit of a challenge, however, to spot those companies that have...</p>\n\n<a href=\"https://www.fool.com/investing/2023/11/14/3-growth-stocks-to-buy-that-could-be-massive-long/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F754664%2Finvesting-screen-analysis-investor-growth-stocks.jpg&op=resize&w=165&h=104","relate_stocks":{"LU0109392836.USD":"富兰克林科技股A","NVDA":"英伟达","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","BK4585":"ETF&股票定投概念","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4543":"AI","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","BK4579":"人工智能","BK4550":"红杉资本持仓","BK4141":"半导体产品","BK4503":"景林资产持仓","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","BK4581":"高盛持仓","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0109391861.USD":"富兰克林美国机遇基金A Acc","BK4549":"软银资本持仓","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","BK4548":"巴美列捷福持仓","LU0642271901.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD-H","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0079474960.USD":"联博美国增长基金A","BK4529":"IDC概念","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU0082616367.USD":"摩根大通美国科技A（dist）","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","LU0080751232.USD":"富达环球多元动力基金A","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","BK4592":"伊斯兰概念","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","BK4554":"元宇宙及AR概念","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC"},"source_url":"https://www.fool.com/investing/2023/11/14/3-growth-stocks-to-buy-that-could-be-massive-long/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2383028540","content_text":"It's not terribly difficult to identify the sizzling growth stocks of the moment, drawing heaps of enthusiasm on Wall Street. It can be a bit of a challenge, however, to spot those companies that have long-term staying power and are going to still be thriving many years into the future. It requires a product or service in perpetual demand as well as the capacity to adapt as the marketplace evolves.With that as the backdrop, here's a rundown of three growth stocks that could be massive long-term winners.1. NvidiaYou probably know the name Nvidia (NVDA 2.12%) as a manufacturer of computer hardware -- specifically, a maker of high-performance graphics processors that hardcore video gamers need. The company still makes great graphic cards. As it turns out, though, the same technology is perfectly suited to handle all the calculations needed in artificial intelligence (AI) applications.That's how Nvidia's data center business (which largely serves the AI market) became its single-biggest profit center, accounting for over half of the company's revenue. Superior technology is also how Nvidia became the leader of the world's AI hardware market; some estimates put its market share reach in the ballpark of 90%.And that's what makes this stock such a great long-term prospect -- the AI movement has still only scratched the surface of its potential. Market research outfit Technavio forecasts annualized AI chip market growth of more than 60% through 2027. Nvidia is prepared to capture more than its fair share of this growth by virtue of its software's ability to provide off-the-shelf, turnkey AI solutions. Precedence Research believes the software sliver of the AI market is on pace to grow by an average pace of 23% through 2032.Nvidia shares are seemingly priced at somewhat frothy levels right now -- up more than 300% just since last October's low. Just don't be too stingy or short-sighted if you want in. The analyst community's current consensus target stands at $647.20, which is still 38% above the stock's present price. Nvidia shares' current price is also only a relatively modest 28 times next year's expected per-share earnings. This recent rally is pretty well justified.2. Icon PLCWhile Nvidia may be a household name, Icon PLC (ICLR 3.51%) isn't. There's a very good chance you or someone in your household has benefited from Icon's service, however, without realizing it.In simplest terms, Icon PLC helps more familiar pharmaceutical names develop their drugs. It's a clinical research organization, or CRO, meaning that it handles clinical testing for drug companies that don't want to deal with the distraction or cost of handling such duties on their own. The Ireland-based company solidifies its relationships with add-on services like consulting, any labwork required for a particular trial, and patient recruitment and retention.It's a true win-win, too. That's because the logistics of clinical drug trials are complicated and expensive, particularly for smaller developers that may only be working on a few projects -- or maybe even just one drug. They're also risky. A University of Michigan study in the journal Science Direct points out that 90% of drugs fail to win approval. Of those, roughly half fail because of clinical inefficiency.It's often cheaper, easier, faster, and ultimately safer to punt this work to experts in this sliver of the pharmaceutical market. And Icon's a go-to name in the business. It's already done it all and is good at what it does. More than a decade's worth of mostly uninterrupted revenue growth says so, as do its income and earnings before interest, taxes, depreciation, and amortization (EBITDA) growth histories.ICLR Revenue (Quarterly) data by YCharts.Investors have good reason to expect more of this reliable growth going forward, too. That's because there's never apt to be a time when the world will stop looking for newer and better drugs. The increasing cost and complexity of drug development also work to Icon's advantage.3. Novo NordiskLast but not least (and speaking of pharmaceuticals), shares of Novo Nordisk (NVO -1.41%) offer lots of long-term growth potential. If it seems like you've heard this name being discussed more than usual of late, you're not imagining things. Credit its drugs Ozempic and Wegovy, mostly.Although it was approved back in the middle of 2021, production delays didn't allow weight-loss drug Wegovy to reach the market until late last year. Sales are, unsurprisingly, picking up steam, stoking interest in the stock. Ozempic is a diabetes treatment that's been on the market since 2016, but it's increasingly being prescribed off-label as an obesity drug as well.Eli Lilly's diabetes treatment Mounjaro was also just approved for weight loss, thrusting all of these options into the comparative spotlight and pushing investors into a bit of a frenzy as a result.The thing is, there's arguably enough room in the market for Novo Nordisk and any current or prospective competitors. Goldman Sachs estimates the anti-obesity drug market will swell from around $6 billion this year to a whopping $100 billion as soon as 2030, once more overweight consumers learn about them and their efficacy.Then there's the other reason to step into a Novo Nordisk position for the long haul -- the rest of its portfolio and pipeline. The company is a major player in the diabetes/insulin arena, with its products accounting for around half of the global GLP-1 insulin markets. Much of this business will likely remain intact, too, even if the world starts losing weight thanks to the mainstreaming of weight-loss pills and injections.A research study recently published in The Lancet indicates the number of people living with type 2 diabetes could sell from 529 million now to a worldwide total of more than 1.3 billion by 2050. Novo Nordisk should be able to leverage its existing reach to win more than its fair share of whatever growth awaits.","news_type":1},"isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":241634042953968,"gmtCreate":1700021093782,"gmtModify":1700026701663,"author":{"id":"4163116133746432","authorId":"4163116133746432","name":"Fachri Salim","avatar":"https://community-static.tradeup.com/news/878ebcbca71067e86825377dd1791b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4163116133746432","authorIdStr":"4163116133746432"},"themes":[],"htmlText":"\"Jika keberhasilan adalah kunci kesuksesan, maka mungkin&nbsp;di dunia ini banyak orang&nbsp;yang tidak sukses karna egonya\"","listText":"\"Jika keberhasilan adalah kunci kesuksesan, maka mungkin&nbsp;di dunia ini banyak orang&nbsp;yang tidak sukses karna egonya\"","text":"\"Jika keberhasilan adalah kunci kesuksesan, maka mungkin di dunia ini banyak orang yang tidak sukses karna egonya\"","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/241634042953968","isVote":1,"tweetType":1,"viewCount":114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":241646362833088,"gmtCreate":1700024197848,"gmtModify":1700027131107,"author":{"id":"4163116133746432","authorId":"4163116133746432","name":"Fachri Salim","avatar":"https://community-static.tradeup.com/news/878ebcbca71067e86825377dd1791b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4163116133746432","idStr":"4163116133746432"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/241646362833088","repostId":"2383047746","repostType":2,"isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":241636781736168,"gmtCreate":1700021760032,"gmtModify":1700026846468,"author":{"id":"4163116133746432","authorId":"4163116133746432","name":"Fachri Salim","avatar":"https://community-static.tradeup.com/news/878ebcbca71067e86825377dd1791b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4163116133746432","idStr":"4163116133746432"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/241636781736168","repostId":"2383028540","repostType":2,"isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":241634042953968,"gmtCreate":1700021093782,"gmtModify":1700026701663,"author":{"id":"4163116133746432","authorId":"4163116133746432","name":"Fachri Salim","avatar":"https://community-static.tradeup.com/news/878ebcbca71067e86825377dd1791b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4163116133746432","idStr":"4163116133746432"},"themes":[],"htmlText":"\"Jika keberhasilan adalah kunci kesuksesan, maka mungkin&nbsp;di dunia ini banyak orang&nbsp;yang tidak sukses karna egonya\"","listText":"\"Jika keberhasilan adalah kunci kesuksesan, maka mungkin&nbsp;di dunia ini banyak orang&nbsp;yang tidak sukses karna egonya\"","text":"\"Jika keberhasilan adalah kunci kesuksesan, maka mungkin di dunia ini banyak orang yang tidak sukses karna egonya\"","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/241634042953968","isVote":1,"tweetType":1,"viewCount":114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}